Singular Genomics Programs (OMIC) ($60MM market cap) is an early stage medical gadget firm, they’ve one industrial product (G4) and one in improvement (G4X) that may be a promising subsequent era genome sequencer. The corporate burns fairly a bit of money, roughly $25MM 1 / 4, however with the industrial launch of G4X in Q2 2025, OMIC may very well be coming to an inflection level with revenues coming in 2025. Previous to bidders showing, the inventory traded at an enormous low cost to money.
Latest Occasions:
- Again on 9/12, very long time investor in OMIC and huge well being care fund, Deerfield Administration, made a $10/share bid for OMIC. Shares traded for about $5.60/share earlier than the provide.
- Following Deerfield’s bid, on 9/19, our good friend Kevin Tang lobbed in his personal $12/share bid, he owns slightly below 15% of the corporate.
- Presumably there was a reasonably aggressive bidding course of (and sure not less than one further bidder apart from Deerfield or Tang, Tang does not really need the IP usually it appears which might cap him out right here) following 9/14 as a result of on 11/4, we came upon that Deerfield’s newest bid is a whooping $24/share and has entered into an exclusivity interval with OMIC to finalize a definitive settlement.
As beforehand disclosed, on September 5, 2024, Deerfield Non-public Design Fund IV, Deerfield Mgmt IV and Deerfield Administration (collectively, “Deerfield”) submitted a non-binding proposal (the “September 2024 Proposal”) to the particular committee of impartial administrators of the Firm (the “Particular Committee”). The September 2024 Proposal associated to a proposed acquisition via a particular objective automobile to be established by Deerfield of all the excellent shares of Widespread Inventory not already owned by Deerfield or some other stockholders or members of administration that Deerfield invitations to “rollover” their present fairness shares. Following negotiations with the Particular Committee in a aggressive course of, Deerfield proposed an elevated buy value of $24.00 per share (the Authentic Proposal, as so modified, the “Modified Proposal” and the transaction contemplated thereby, the “Modified Transaction”), and following such proposed enhance, on October 31, 2024, the Firm and Deerfield entered into an exclusivity settlement to facilitate completion of Deerfield’s due diligence and the preparation and negotiation of definitive agreements in respect of the Modified Transaction.
Draw back may very well be fairly appreciable right here, however we do have a top quality counterparty in Deerfield, aggressive course of and regardless of the sharp enhance within the bid, I nonetheless have Deerfield selecting up OMIC beneath an estimated NCAV at deal shut in the event you exclude the leases.
Together with the working lease, NCAV is nearer to $20/share.
To me this can be a related commerce to Asensus Surgical (ASXC), a money burning enterprise being led into the arms of a creditable purchaser that is aware of it nicely. I purchased shares round $21.50, or a 11.6% unfold to the $24.00 present bid. Relying on the place this trades it won’t be actionable. I might most likely be a purchaser beneath $22.00, we’ll see the place the worth settles in anticipation of the subsequent piece of stories. There is a slight likelihood of one other bump, however not relying on that.
Disclosure: I personal shares of OMIC
